CN102961725B - Agentia for treating dysthymia - Google Patents
Agentia for treating dysthymia Download PDFInfo
- Publication number
- CN102961725B CN102961725B CN201210534850.0A CN201210534850A CN102961725B CN 102961725 B CN102961725 B CN 102961725B CN 201210534850 A CN201210534850 A CN 201210534850A CN 102961725 B CN102961725 B CN 102961725B
- Authority
- CN
- China
- Prior art keywords
- parts
- agentia
- rhizoma
- dysthymia
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an agentia for treating dysthymia. The agentia comprises the following active ingredients in parts by weight: 1-10 parts of Chinese mahonia, 10-20 parts of herba dracocephali integrifolii, 10-30 parts of syzygium aromaticum, 10-30 parts of cowherb seeds, 5-15 parts of pericarpium arecae, 5-10 parts of radix sileris, 5-15 parts of rhizoma dioscoreae, 10-20 parts of fructus ligustri lucidi, 10-20 parts of dried ginger, 10-20 parts of semen hyoscyami, 1-10 parts of rhizoma gastrodiae, 10-20 parts of fructus polygoni orientalis, 1-10 parts of crotalaria sessiliflora, 1-10 parts of radix glycyrrhizae and 1-15 parts of bighead atractylodes rhizome. Proved through clinical applications, the agentia for treating dysthymia has the advantages of being fast to act, obvious in curative effect, good in tolerance, low in cost, and free from any toxic or side effect.
Description
Technical field
The present invention relates to psychosis prevention field, specifically, relate to a kind of medicament for the treatment of dysthymia.
Background technology
Dysthymia main manifestations is that interest goes down, retardation of thinking and speech action reduce, and primary disease women is more than male.Paathogenic factor comprises: inherited genetic factors, physical factors, Nervous and Mental Factors, psychosocial factor etc.The risk of depression is very big, and major depression has 15% homicide rate.Because modern people's rhythm of life is accelerated, mental pressure increases, and the sickness rate of dysthymia obviously increases before.Also because people are not enough to the understanding of primary disease, the symptom showing for this type of patient, most people is thought because intention is little, due to my personality, often failing to give attention to, this is a kind of disease, so, at present not high to this sick diagnosis, there is quite a few patient to can not get clinical diagnosis, so just can not get effective treatment.
Summary of the invention
The object of this invention is to provide a kind of medicament for the treatment of dysthymia.
In order to realize object of the present invention, the invention provides a kind of medicament for the treatment of dysthymia, it is to be made by weight by following bulk drugs: Mahonia fortunei (Lindl.) Fedde 1-10 part, Herba Dracocephali Integrifolii 10-20 part, Flos Caryophylli 10-30 part, Semen Vaccariae 10-30 part, Pericarpium Arecae 5-15 part, Radix Saposhnikoviae 5-10 part, Rhizoma Dioscoreae 5-15 part, Fructus Ligustri Lucidi 10-20 part, Rhizoma Zingiberis 10-20 part, Semen Hyoscyami 10-20 part, Rhizoma Gastrodiae 1-10 part, Fructus Polygoni Orientalis 10-20 part, Herba Crotalariae sessiliflorae 1-10 part, Radix Glycyrrhizae 1-10 part and Rhizoma Atractylodis Macrocephalae 1-15 part.
Preferably, the medicament for the treatment of dysthymia of the present invention is to be made by weight by following bulk drugs: 10 parts of 5 parts of Mahonia fortunei (Lindl.) Fedde, 15 parts of Herba Dracocephali Integrifoliis, 20 parts of Flos Caryophyllis, 20 parts of Semen Vaccariae, 10 parts of Pericarpium Arecae, 10 parts of Radix Saposhnikoviaes, 10 parts of Rhizoma Dioscoreaes, 15 parts of Fructus Ligustri Lucidi, 15 parts of Rhizoma Zingiberiss, 20 parts of Semen Hyoscyamis, 10 parts, Rhizoma Gastrodiae, 15 parts of Fructus Polygoni Orientaliss, 5 parts of Herba Crotalariae sessiliflorae, 5 parts, Radix Glycyrrhizae and the Rhizoma Atractylodis Macrocephalaes.
Preferably, described medicament is tablet, dispersible tablet, instant, decoction or granule.
In the medicament for the treatment of dysthymia of the present invention, use natural drug, through clinical practice, find, have effect rapidly, therapeutic effect obviously, better tolerance, advantage with low cost, without any side effects.
The specific embodiment
Below the invention will be further described for the description by the specific embodiment, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, can make various modifications or improvement, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The preparation of embodiment 1 decoction of the present invention
Get 100 grams of 50 grams of Mahonia fortunei (Lindl.) Fedde, 150 grams of Herba Dracocephali Integrifoliis, 200 grams of Flos Caryophyllis, 200 grams of Semen Vaccariae, 100 grams of Pericarpium Arecae, 100 grams of Radix Saposhnikoviaes, 100 grams of Rhizoma Dioscoreaes, 150 grams of Fructus Ligustri Lucidi, 150 grams of Rhizoma Zingiberiss, 200 grams of Semen Hyoscyamis, 100 grams, Rhizoma Gastrodiae, 150 grams of Fructus Polygoni Orientaliss, 50 grams of Herba Crotalariae sessiliflorae, 50 grams, Radix Glycyrrhizae and the Rhizoma Atractylodis Macrocephalaes, add 3000 ml waters, under the condition of 1 normal atmosphere, backflow, heat 5 hours.Be cooled to room temperature, filter, filtrate is decoction of the present invention.
Test example
66 routine dysthymia patients are divided into treatment group and matched group, treatment group 32 examples, male's 5 examples wherein, women's 27 examples, the oldest person 52 years old, reckling 16 years old, 36 years old mean age; Matched group 34 examples, male's 4 examples wherein, women's 30 examples, the oldest person 50 years old, reckling 18 years old, 34 years old mean age.The elder of the treatment group course of disease 12 years, the shortest person 1 year; The elder of the matched group course of disease 9 years, the shortest person 11 months.Two groups in sex, age, the course of disease without significant difference (P > 0.05), there is comparability.
Diagnostic criteria
Diagnostic criteria: reference literature < < Chen Haozhu. practical internal medicine [M]. the 12nd edition ._ Beijing: People's Health Publisher, 2005.2770-2770) > > drafts: (1) take mental state low be main clinical phase, can be from depressed to extremely grieved, even numb.(2) with corresponding thinking and behavior, obviously reduce at least 4 of the following symptoms of concrete manifestation: 1. hebetude, without happy sense; 2. energy obviously reduces or tired sense; 3. psychomotor activity is blunt or intense; 4. self evaluation is too low, thinks highly of oneself or feeling of guilt; 5. association difficulty, or conscious elaborative faculty declines; 6. repeatedly there is the thought of wanting to die, or suicide, autolesionism; 7. sleep disorder is as insomnia, early awakening or hypersomnia; 8. hyposexuality.
Therapeutic Method
Above-mentioned treatment group and matched group are observed to 3 months time.The decoction of oral embodiment 1 preparation for the treatment of group, every day 2 times, each 50 milliliters.Matched group oral hydrochloride Paroxetine (production of GlaxoSmithKline PLC (Tianjin) company limited), every day 2 times, 200 milligrams of each dosage.In therapeutic process, forbid other drug.
Criterion of therapeutical effect
According to < < State Administration of Traditional Chinese Medicine. disease of tcm Standardization of diagnosis and curative effect [S]. Nanjing: Nanjing University publishes, and 2010:34 > > formulates criterion of therapeutical effect.(1) cure: language, manner are normal, and look stable, can normal process routine matter.(2) take a turn for the better: look stable, language, manner normal, or be improved.(3) do not heal: spirit, language, behave strangely, can not control.
Therapeutic outcome
The result for the treatment of after 3 months is as shown in table 1 below.
The comparison of table 1 liang group curative effect
Note: learn and process by statistics, X
2=2.878, P < 0.05, treatment group curative effect is obviously better than matched group, has comparability.
Untoward reaction
In matched group, observe 3 examples and occur sialorrhea, feeling sick appears in 4 examples, vomiting, and abnormal liver function appears in 1 example, and electrocardiographic abnormality appears in 1 example.And in treatment group, do not find any untoward reaction.As can be seen here, the untoward reaction for the treatment of group is significantly less than the untoward reaction of matched group.
Claims (1)
1. a medicament for the treatment of dysthymia, it is characterized in that, it is to be made by weight by following bulk drugs: 10 parts of 5 parts of Mahonia fortunei (Lindl.) Fedde, 15 parts of Herba Dracocephali Integrifoliis, 20 parts of Flos Caryophyllis, 20 parts of Semen Vaccariae, 10 parts of Pericarpium Arecae, 10 parts of Radix Saposhnikoviaes, 10 parts of Rhizoma Dioscoreaes, 15 parts of Fructus Ligustri Lucidi, 15 parts of Rhizoma Zingiberiss, 20 parts of Semen Hyoscyamis, 10 parts, Rhizoma Gastrodiae, 15 parts of Fructus Polygoni Orientaliss, 5 parts of Herba Crotalariae sessiliflorae, 5 parts, Radix Glycyrrhizae and the Rhizoma Atractylodis Macrocephalaes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210534850.0A CN102961725B (en) | 2012-12-06 | 2012-12-06 | Agentia for treating dysthymia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210534850.0A CN102961725B (en) | 2012-12-06 | 2012-12-06 | Agentia for treating dysthymia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102961725A CN102961725A (en) | 2013-03-13 |
| CN102961725B true CN102961725B (en) | 2014-03-12 |
Family
ID=47792344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210534850.0A Expired - Fee Related CN102961725B (en) | 2012-12-06 | 2012-12-06 | Agentia for treating dysthymia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102961725B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406913A (en) * | 2011-11-28 | 2012-04-11 | 荣成市交通诊所 | Chinese medicinal composition for treating melancholia |
-
2012
- 2012-12-06 CN CN201210534850.0A patent/CN102961725B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102961725A (en) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102764340A (en) | Traditional Chinese medicine composite capable of improving sleep and preparation method and application thereof | |
| CN101530579B (en) | A pharmaceutical composition for soothing the nerves | |
| CN103599474B (en) | A kind of Chinese medicine composition being used for the treatment of poor sleeping quality | |
| CN101579511B (en) | Drug combination used for treating schizophrenia | |
| CN104758686A (en) | Traditional Chinese medicine preparation for treating poor sleep quality | |
| CN105456582A (en) | Traditional Chinese medicine for treating depressive disorder and anxiety disorder | |
| CN104706881A (en) | Health product with sleep adjusting function | |
| CN102961725B (en) | Agentia for treating dysthymia | |
| CN107837384A (en) | A kind of Chinese medicine composition for treating hand-foot-and-mouth disease | |
| CN103860894B (en) | A kind of medicine for the treatment of chronic prostatitis | |
| CN103550477B (en) | Medicament for treating herpes zoster | |
| CN104547851B (en) | One treats hypertensive medicine | |
| CN104940889B (en) | Traditional Chinese medicine preparation for patients with internal medicine neurosis | |
| CN102488808B (en) | Traditional Chinese medicine capsule for treating ischemic cerebrovascular disease | |
| CN102416147B (en) | Medicinal composition for treating mania of patients abstained from drugs | |
| CN101653579A (en) | Traditional Chinese medicine preparation for treating intractable insomnia | |
| CN102961726B (en) | Agentia for treating schizophrenia | |
| CN105998335A (en) | Tranquilizing traditional Chinese medicine composition gel and preparation method thereof | |
| CN102488797B (en) | Medicinal composition for treating dysmenorrhea | |
| CN102114149A (en) | Chinese medicine preparation for treating epilepsy | |
| CN101385836B (en) | Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof | |
| Tian et al. | Effects of Bushen Huoxue formula on the learning and memory function and the cerebral neurotransmitters in diabetic mice | |
| CN104784332B (en) | A kind of preparation method of the medicament treating Chronic Urinary Tract Infection | |
| CN102961452A (en) | Medicinal composition for relieving depression and preparation method thereof | |
| CN102552581B (en) | Medicament for treating insomnia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140312 Termination date: 20151206 |
|
| EXPY | Termination of patent right or utility model |